Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1995 Jun;73(6):506–510. doi: 10.1136/hrt.73.6.506

Left ventricular volumes, ejection fraction, and plasma proatrial natriuretic factor (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. CONSENSUS II Multi-Echo Study Group.

V V Bonarjee 1, T Omland 1, D W Nilsen 1, S Carstensen 1, J Berning 1, M Edner 1, K Caidahl 1
PMCID: PMC483910  PMID: 7626347

Abstract

OBJECTIVES--To assess whether the reduction in left ventricular dilatation after acute myocardial infarction obtained by early administration of angiotensin converting enzyme inhibitors depends on continuous treatment. DESIGN--Prospective observational and cross sectional study of withdrawal of randomised treatment with enalapril or placebo. PATIENTS--106 patients on 6 months trial treatment after an acute myocardial infarction. MAIN OUTCOME MEASURES--Left ventricular volumes and ejection fraction as assessed by echocardiography and circulating proatrial natriuretic factor (1-98) before and 4-6 weeks after withdrawal of treatment. RESULTS--There were no significant changes (mean (SD)) in left ventricular systolic (0.7 (4.7) ml/m2) and diastolic (0.4 (6.6) ml/m2) volume indices, ejection fraction (-0.9 (6)%), and proatrial natriuretic factor (172 (992) pmol/l) after withdrawal of enalapril. The significantly lower left ventricular volumes observed with 6 months of enalapril therapy after acute myocardial infarction, as compared with placebo, were maintained 6 weeks after drug withdrawal. CONCLUSION--The results show that the benefit of 6 months of enalapril treatment initiated early after myocardial infarction is maintained for at least 6 weeks after drug withdrawal, suggesting that the treatment effect on left ventricular structure is not reversed by changes in loading conditions caused by subsequent drug withdrawal.

Full text

PDF
506

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonarjee V. V., Carstensen S., Caidahl K., Nilsen D. W., Edner M., Berning J. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. Am J Cardiol. 1993 Nov 1;72(14):1004–1009. doi: 10.1016/0002-9149(93)90853-5. [DOI] [PubMed] [Google Scholar]
  2. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  3. Gaudron P., Eilles C., Kugler I., Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation. 1993 Mar;87(3):755–763. doi: 10.1161/01.cir.87.3.755. [DOI] [PubMed] [Google Scholar]
  4. Grinstead W. C., Young J. B. The myocardial renin-angiotensin system: existence, importance, and clinical implications. Am Heart J. 1992 Apr;123(4 Pt 1):1039–1045. doi: 10.1016/0002-8703(92)90715-8. [DOI] [PubMed] [Google Scholar]
  5. Hirsch A. T., Talsness C. E., Schunkert H., Paul M., Dzau V. J. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991 Aug;69(2):475–482. doi: 10.1161/01.res.69.2.475. [DOI] [PubMed] [Google Scholar]
  6. Konstam M. A., Kronenberg M. W., Rousseau M. F., Udelson J. E., Melin J., Stewart D., Dolan N., Edens T. R., Ahn S., Kinan D. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993 Nov;88(5 Pt 1):2277–2283. doi: 10.1161/01.cir.88.5.2277. [DOI] [PubMed] [Google Scholar]
  7. Konstam M. A., Rousseau M. F., Kronenberg M. W., Udelson J. E., Melin J., Stewart D., Dolan N., Edens T. R., Ahn S., Kinan D. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992 Aug;86(2):431–438. doi: 10.1161/01.cir.86.2.431. [DOI] [PubMed] [Google Scholar]
  8. Lerman A., Gibbons R. J., Rodeheffer R. J., Bailey K. R., McKinley L. J., Heublein D. M., Burnett J. C., Jr Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993 May 1;341(8853):1105–1109. doi: 10.1016/0140-6736(93)93125-k. [DOI] [PubMed] [Google Scholar]
  9. Mathisen P., Hall C., Simonsen S. Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest. 1993 Feb;53(1):41–49. doi: 10.1080/00365519309092530. [DOI] [PubMed] [Google Scholar]
  10. Omland T., Bonarjee V. V., Nilsen D. W., Sundsfjord J. A., Lie R. T., Thibault G., Dickstein K. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J. 1993 Nov;70(5):409–414. doi: 10.1136/hrt.70.5.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pfeffer M. A., Lamas G. A., Vaughan D. E., Parisi A. F., Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988 Jul 14;319(2):80–86. doi: 10.1056/NEJM198807143190204. [DOI] [PubMed] [Google Scholar]
  12. Pflugfelder P. W., Baird M. G., Tonkon M. J., DiBianco R., Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol. 1993 Nov 15;22(6):1557–1563. doi: 10.1016/0735-1097(93)90578-o. [DOI] [PubMed] [Google Scholar]
  13. Picard M. H., Wilkins G. T., Ray P. A., Weyman A. E. Natural history of left ventricular size and function after acute myocardial infarction. Assessment and prediction by echocardiographic endocardial surface mapping. Circulation. 1990 Aug;82(2):484–494. doi: 10.1161/01.cir.82.2.484. [DOI] [PubMed] [Google Scholar]
  14. Pirolo J. S., Hutchins G. M., Moore G. W. Infarct expansion: pathologic analysis of 204 patients with a single myocardial infarct. J Am Coll Cardiol. 1986 Feb;7(2):349–354. doi: 10.1016/s0735-1097(86)80504-6. [DOI] [PubMed] [Google Scholar]
  15. Raine A. E., Erne P., Bürgisser E., Müller F. B., Bolli P., Burkart F., Bühler F. R. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986 Aug 28;315(9):533–537. doi: 10.1056/NEJM198608283150901. [DOI] [PubMed] [Google Scholar]
  16. Sharpe N., Smith H., Murphy J., Greaves S., Hart H., Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991 Apr 13;337(8746):872–876. doi: 10.1016/0140-6736(91)90202-z. [DOI] [PubMed] [Google Scholar]
  17. Sundsfjord J. A., Thibault G., Larochelle P., Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab. 1988 Mar;66(3):605–610. doi: 10.1210/jcem-66-3-605. [DOI] [PubMed] [Google Scholar]
  18. Swedberg K., Held P., Kjekshus J., Rasmussen K., Rydén L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med. 1992 Sep 3;327(10):678–684. doi: 10.1056/NEJM199209033271002. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES